Morepen Laboratories

Morepen Laboratories EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Morepen Laboratories (MOREPENLAB.NS) as of Oct 23, 2026 is 1.74 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.59 B INR — a change of 9.74% (higher).

EBITDA

1.74 BINR

YoY

9.74%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Morepen Laboratories is 2025 1.74 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Morepen Laboratories was 2024 1.59 B INR. It decreases by 9.74% higher compared to the previous year.

The Morepen Laboratories EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
647.06 M INR
Jan 1, 2019
675.15 M INR
Jan 1, 2020
685.09 M INR
Jan 1, 2021
1.19 B INR
Jan 1, 2022
1.37 B INR
Jan 1, 2023
795.33 M INR
Jan 1, 2024
1.59 B INR
Jan 1, 2025
1.74 B INR
The Morepen Laboratories EBITDA history
YEAREBITDAYoY
1.74 BINR+9.74%
1.59 BINR+99.44%
795.33 MINR-41.79%
1.37 BINR+15.27%
1.19 BINR+73.02%
685.09 MINR+1.47%
675.15 MINR+4.34%
647.06 MINR+5.43%
613.75 MINR+7.36%
571.67 MINR+16.53%
490.57 MINR+0.06%
490.30 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morepen Laboratories Stock analysis

What does Morepen Laboratories do? Morepen Laboratories Ltd. generates revenue through the manufacturing and marketing of bulk drugs, pharmaceutical formulations, and home health products. The company produces active pharmaceutical ingredients (APIs) such as Apixaban, Edoxaban, Sitagliptin, and Rivaroxaban, which are sold to other pharmaceutical manufacturers. Its finished formulations, including Intebact Capsules, Intelicaps Lax, and Rythmix Kid Syrup, are marketed under its own brand for direct consumer sales. Home health products like the Dr. Morepen 49W Room Air Purifier and Dr. Morepen VP06 Breathe Free Vaporizer are sold directly to consumers through retail channels. The company's subsidiaries, Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited, support these product lines by handling specific manufacturing and distribution tasks. The primary customers for APIs are pharmaceutical companies seeking bulk ingredients for their own formulations. Finished formulations target healthcare consumers and pharmacies, while home health products are sold to households and medical facilities. The company's product segments are clearly divided: APIs for industrial clients, branded formulations for retail consumers, and home health devices for personal use. This segmentation allows Morepen to serve multiple market segments without overlapping product lines. Morepen's revenue streams are diversified across three main areas: API sales to pharmaceutical manufacturers, direct-to-consumer sales of branded formulations, and retail sales of home health products. The company's subsidiaries play a key role in supporting each segment, with Dr. Morepen Limited handling branded formulations, Morepen Devices Limited managing home health devices, and Total Care Limited likely supporting broader healthcare services. This structure ensures that each product line is efficiently managed and marketed to its respective target audience. Morepen Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Morepen Laboratories stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Morepen Laboratories is 1.74 B INR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Morepen Laboratories changed from 1.59 B INR to 1.74 B INR, representing a 9.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Morepen Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Morepen Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Morepen Laboratories

All Key Metrics — Morepen Laboratories